Armistice Capital Reports 3.76% Stake in AngioDynamics (ANGO)

Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO).

Rhea-AI Filing Summary

Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.

Positive

• Transparent disclosure of beneficial ownership and the relationship between Armistice Capital, the Master Fund, and Steven Boyd
• Position is passive and under 5%, indicating no immediate intent to influence control

Negative

• None.

Insights

Securities Analyst

TL;DR: Institutional manager reports a non-controlling 3.76% position, disclosed for regulatory transparency.

The Schedule 13G/A shows Armistice Capital, via its Master Fund, holds 1,527,815 AngioDynamics shares representing 3.76% of the reported float. This level is below the 5% threshold that typically triggers Schedule 13D obligations, indicating a passive investor posture. The filing clarifies voting and dispositive powers are exercised by Armistice under an investment management agreement and that holdings are ordinary-course investments, which reduces the likelihood of imminent activism or control attempts.

Corporate Governance Expert

TL;DR: Disclosure aligns with governance norms; no material control implications.

The joint filing and certifications are standard: Armistice and Steven Boyd file jointly and disclaim control beyond managerial authority. The explicit statement that the Master Fund disclaims beneficial ownership due to its agreement with Armistice is important for legal clarity. Because the position is under 5% and accompanied by a passive declaration, this is a routine ownership disclosure with limited immediate governance impact.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AngioDynamics (ANGO) shares does Armistice Capital report owning?

The filing reports 1,527,815 shares beneficially owned by the Reporting Persons.

What percentage of ANGO does the reported position represent?

The position represents 3.76% of the class, based on 40,633,885 shares outstanding as of May 31, 2025.

Does Armistice Capital claim control of AngioDynamics?

No. The filing states the holdings were acquired and are held in the ordinary course of business and not to change or influence control.

Who holds the shares directly and who manages voting rights?

The Armistice Capital Master Fund Ltd. is the direct holder; Armistice Capital, as investment manager, exercises voting and investment power under an investment management agreement.

When was the Schedule 13G/A signed?

The signatures are dated August 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 08:55 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ANGIODYNAMICS INC

(Name of Issuer)

Common Stock, par value $.01

(Title of Class of Securities)

03475V101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03475V101

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,527,815.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,527,815.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,527,815.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.76 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 03475V101

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,527,815.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,527,815.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,527,815.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.76 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ANGIODYNAMICS INC
(b)	Address of issuer's principal executive offices: 14 PLAZA DRIVE, LATHAM, NY, 12110
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock, par value $.01
(e)	CUSIP No.: 03475V101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,527,815
(b)	Percent of class: 3.76 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,527,815
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,527,815 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 40,633,885 Shares outstanding as of May 31, 2025, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on July 18, 2025. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	08/14/2025

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	08/14/2025

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd